


Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis


WASHINGTON, September 13, 2017

Supplemental Materials


Continuous	ITT population				
		Tradipitant	Placebo	Diff	p-value
<i>A. Itch Outcomes</i>	Average Itch VAS	-41.5	-35.8	-5.7	0.306
	Worst Itch VAS	-44.2	-30.6	-13.6	0.019
	Worst Itch NRS Night	-3.4	-2.4	-1.1	0.029
	Worst Itch NRS Day	-3.3	-2.5	-0.8	0.074
<i>B. Disease Outcomes</i>	SCORAD Total	-21.3	-13.6	-7.7	0.008
	Objective SCORAD	-13.3	-7.2	-6.1	0.005
	Subjective SCORAD	-8.1	-6.7	-1.4	0.157
<i>C. General Impression Outcomes</i>	CGI-C	2.6	3.3	-0.7	0.007
	PGI-C Itch	2.6	3.2	-0.6	0.025
	PGI-C AD	2.7	3.4	-0.7	0.007
<i>D. Quality of Life Outcomes</i>	PBI	1.7	1.2	0.5	0.038
	SKINDEX 16	-34.8	-26.6	-8.2	0.102
Categorical	ITT population				
		Tradipitant	Placebo	Diff	p-value
<i>A. Itch Outcomes</i>	Worst Itch VAS >=40	52.6%	34.7%	17.9%	0.037
	worst Itch VAS >=30	56.6%	38.9%	17.7%	0.049
<i>B. Disease Outcomes</i>	SCORAD >=50%	44.0%	20.8%	23.2%	0.004
	EASI >=75%	21.1%	11.1%	10.0%	0.067



* Values are multiplied by 10 for the purpose of display



Worst Itch VAS - Tradipitant vs Placebo



Total SCORAD – Tradipitant vs Placebo

